Cardiovascular disease diagnostics a global Strategic Business Report
|
Спампаваць 85.33 Kb.
|
窗体顶端
CARDIOVASCULAR DISEASE DIAGNOSTICS - A Global Strategic Business Report联系购买电话：010-82863480 公司名称：佐思信息 公司地址：北京市海淀区苏州街18号院长远天地大厦A2座 1008-1室（100080） 出版日期：February 2011 This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom閞ieux, Cambridge Heart, Inc., Cholestech Corp., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc., Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. TABLE OF CONTENTS CARDIOVASCULAR DISEASE DIAGNOSTICS (Complete Report) Pages : 477 | 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......13 Study Reliability and Reporting Limitations.......1 Disclaimers.......2 Data Interpretation & Reporting Level.......3 Quantitative Techniques & Analytics.......3 Product Definitions and Scope of Study.......3 In Vitro Diagnostics.......3 In Vivo Diagnostics.......3 2. INDUSTRY OVERVIEW.......56 Cardiovascular Diseases: The Undying Challenge.......51 Table 1: Region-Wise Incidence and Prevalence of Cardiovascular Diseases in 2006.......6 Mounting Healthcare Costs - Calls for Early Diagnosis.......6 Cardiovascular Disease Diagnostics: Playing a Pivotal Role in Early Disease Detection.......61 Developed Countries Dominate, Developing to be the Future Growth Engine.......7 Fast and Accurate Diagnosis ?Reduce Unnecessary Healthcare Costs.......71 POC Diagnostics Market Gains Momentum.......8 Cardiac Markers - Making Diagnosis Easier and Quicker.......81 Major Cardiac Markers and their Properties.......9 What抯 New in POC Cardiac Markers Space?.......91 Leading Players.......10 List of Point of Care Cardiac Marker Testing Products.......101 3. IN-VIVO DIAGNOSTICS.......114 Table 2: Global In-vivo Cardiovascular Disease Diagnostics Market by Region: 2010 (includes corresponding Graph/Chart).......11 Novel Imaging Techniques Boost In vivo Diagnostics Market.......111 Non-Invasive Procedure Hogs the Limelight for Cardiovascular Treatment.......12 Cardiology Diagnostic Imaging.......12 New Technologies Bring Diagnostics Closer to Patients.......121 Trends Cited in the Imaging Technologies Market.......13 CT Scanners.......131 MRI.......14 Move Towards Efficient Patient Data Management.......141 4. IN-VITRO DIAGNOSTICS.......156 A Quick Insight into the Global In-vitro Diagnostics Market.......15 Growth Trends.......15 Developed Countries Drive In-Vitro Diagnostics (IVD) Market.......151 Table 3: Leading In-Vitro Diagnostics Markets Worldwide (2007): Percentage Breakdown for North America, Europe, Japan, and Others (includes corresponding Graph/Chart).......16 Established Players Dominate the Fragmented Market.......16 Table 4: Leading Players in the Global In-Vitro Diagnostics Market (2009): Percentage Breakdown of Value Sales for Roche Diagnostics, Abbott Diagnostics, Ortho/ LifeScan, Bayer/Siemens, Beckman Coulter, BD, Dade Behring, bioMerieux and Others (includes corresponding Graph/Chart).......161 Point-of-Care In-Vitro Testing on the Roll.......17 Table 5: Global In vitro Diagnostics Market by Type of Test (2007): Percentage Breakdown for Central Lab Testing, Point-of-Care Testing, and Molecular Testing (includes corresponding Graph/Chart).......17 A Specific Focus on Global Cardiovascular In-Vitro Diagnostics Market.......171 Market Analysis.......18 Table 6: World Cardiovascular In-vitro Diagnostics Market: 2010 (includes corresponding Graph/Chart).......18 Aging Population Drives Home Testing Market.......181 Cholesterol and Other Cardiovascular Test Kits Offered by Leading Companies.......19 Development of Home Cholesterol Testing Kits.......19 Table 7: Global Cholesterol Point-of-Care Rapid Tests Market (2009): Market Shares of Leading Players by Value Sales for Inverness Medical, Roche, Abaxis, and Others (includes corresponding Graph/Chart).......19 Strong Demand for Risk Assessment Markers.......191 Advancements in Alternate-Site Coagulation Monitoring.......201 5. CVD - CAUSE AND RISK FACTORS.......217 CVD - Global Facts.......21 Table 8: CVD Death Rates (per 100,000 population) Among Men (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart).......211 Table 9: CVD Death Rates (per 100,000 population) Among Women (Aged 35-74 years) by Select Country: 2007 (includes corresponding Graph/Chart).......22 Atherosclerosis - Leading Cause for CVD.......22 Risk Factors.......22 Irreversible Risk Factors.......22 Increasing age.......221 Sex (gender).......23 Heredity (including Race).......23 Risk Factors that can be controlled.......23 Tobacco Smoke.......23 High Blood Cholesterol.......231 LDL Cholesterol.......24 HDL Cholesterol.......24 Triglyceride levels.......241 Hypercholesterolemia - Conditions Associated with Cholesterol Level.......25 High Blood Pressure.......251 BP - Leading Cause of Cardiovascular Disease in Young Adults.......26 Physical Inactivity.......26 Obesity and Overweight.......26 Diabetes Mellitus.......26 Cardiovascular Disease and Homocysteine Levels.......261 Measures for Reducing Cardiovascular Diseases.......271 6. CARDIOVASCULAR DISEASE AND CONDITIONS.......283 Angina Pectoris.......28 Arrhythmias.......28 Sudden Cardiac Death (SCD).......28 Stroke.......281 Congestive Heart Failure.......29 Heart Failure Classification as per the NYHA and ACC/AHA.......291 Table 10: Prevalence Rates of Congestive Heart Failure in Select Countries (per 10,000) (includes corresponding Graph/Chart).......30 Cardiovascular Disease Involving Transplant Patients.......301 7. DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES.......3112 In-Vitro Cardiovascular Diagnostics.......31 Cholesterol Testing.......31 Use of Markers.......31 Creatine Kinase MB.......311 Troponin T and Troponin I.......32 C-Reactive Protein.......321 Plasminogen Activator Inhibitor-1.......33 D-Dimer.......33 Thrombus Precursor Protein.......33 Other Cardiac Markers.......33 Increasing Popularity of Risk Assessment Markers.......331 A Step Forward in Cardiovascular Risk Assessment.......34 In Vivo Diagnostic Tests.......34 Computed Imaging / Tomography.......34 Electron Beam Computed Tomography (EBCT).......341 Appropriate Conditions for EBCT Diagnosis.......35 Cardiac Positron Emission Tomography (PET).......351 Digital Cardiac Angiography/ Digital Subtraction Angiography.......36 Magnetic Resonance Imaging (MRI).......361 Single Photon Emission Computed Tomography (SPECT).......37 Echocardiography.......37 Different Types of Echo-techniques.......37 M-mode (Motion mode, One-dimensional).......371 Two-Dimensional (Cross-sectional).......38 Stress Echocardiogram (Stress Echo).......38 Transesophageal Echocardiogram (TEE).......38 Risks.......38 Ultrasound Tests.......38 Doppler Ultrasound.......381 Intravascular Ultrasound.......39 Working.......39 Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease.......391 Nuclear Cardiology Tests.......40 Applications.......40 Types of Nuclear Cardiology Tests.......40 Myocardial Perfusion Imaging.......401 Applications.......41 Risks.......41 Ventricular Function Test.......411 Testing Cardiac Stress.......42 Cardio Vascular Disease Diagnostics Tests in the Pipeline.......42 Aderis MRE-0470.......42 CardioMEMS Novel Technology.......42 Technology Platform.......421 8. PRODUCT LAUNCHES AND DEVELOPMENTS.......436 Cardiac Science Launches Microvolt T-Wave Alternans Module.......43 Cleveland HeartLab to Extend Test Menu.......43 St. Jude Medical Introduces EnSite Derexi Module.......431 NorDiag Unveils NorDiags Arrow Instrument.......44 Biosense Webster Launches CARTO?3 System.......44 McKesson Unveils New Variant of Horizon Cardiology Cardiovascular Information System.......44 Correlagen Launches CardioGeneScan Test.......441 Royal Philips Electronics to Launch PageWriter TC50 Cardiograph.......45 Philips Introduces Xcelera R3.1.......45 St. Jude Medical Launches Medical Devices for Heart Rhythms Disorders.......451 TomTec and Medis Launches Cardiac Imaging and Analysis Product.......46 Royal Philips Electronics Launches PageWriter TC70.......461 Philips Healthcare to Introduce CX50 CompactXtreme.......47 Royal Philips Electronics Introduces Xcelera R2.2.......47 Toshiba America to Launch AplioTM Artida.......472 9. PRODUCT LAUNCHES AND DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE BUILDER.......4918 Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner.......49 Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe.......49 GE Healthcare Launches Vivid e Ultrasound Systems.......49 Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis.......491 Siemens Launches Imaging Release for the ACUSON Sequoia Platform.......50 GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000.......50 GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software.......50 GE Healthcare抯 Lightspeed VCT Offers Imaging at 70% Lower Exposure.......501 Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (Outside US).......51 Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias.......51 Siemens Medical Introduces syngo?US, New Echocardiography Solution........51 Dade Behring Introduces CardioPhase?hsCRP Test for Multiple Testing Platforms........511 Shimadzu Launches Two Models in Angiographic Imaging.......52 Omron Healthcare Introduces Non Invasive Vascular Profiling System.......52 Abbott Launches XIENCE V, New Coronary Stent System.......52 Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter .......521 BioM閞ieux Introduces High Performance VIDAS Troponin I Ultra.......53 Siemens Launches Acuson X300 Ultrasound Platform.......53 Siemens Releases Web-Enabled CT.......531 GE Introduces Latest Electrocardiograph Device, MAC 3500.......54 GE Emphasizes on the Striking Features of New Vivid 7 Dimension ?6.......54 GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices.......541 Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators.......55 Philips Introduces Web Based Cardiac Tools.......55 Siemens Showcases Solutions for Cardiac Problems Through Molecular Imaging.......55 Siemens Presents Advancements in Echocardiography.......551 Siemens Debuts syngo BEAT.......56 Siemens Combines syngo?Dynamics with Soarian? for Cardiovascular EPR.......56 GE Healthcare Unveils CardIQ Fusion.......56 GE Introduces Discovery VCT.......56 GE Unveils Dynamic VUE.......561 GE Launches CardIQ Xpress.......57 GE Presents the Ventri for Cardiac Imaging.......57 GE Introduces High Definition Magnetic Resonance System.......57 Dade Behring Unveils CardioPhase(R) hsCRP Test.......57 Siemens Launches Encompass III on C512 Ultrasound Platform.......571 Siemens Launches Four New CT Clinical Engines.......58 Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool.......58 Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx?......58 Philips Introduces HD11 XE Cardiology Ultrasound System.......581 Siemens Introduces Biplane FD Cardiology System.......59 Siemens Introduces Syngo Circulation Software for CT Tomography.......59 Siemens Introduces SOMATOM Definition for Cardiac Imaging.......59 Dade Behring Unveils Homocysteine Test on BN (TM) Systems.......59 Roche Unveils Cardiac pro-BNP Test.......591 Philips Introduces HD11 XE.......60 Corgenix Unveils AtherOx(TM).......60 GE Healthcare Unveils Breakthrough Imaging Technology.......60 Philips Launches Products to Detect Heart Problems.......601 Philips Unveils Computed Tomography and EP Planning package.......61 Philips Widens Magnetic Resonance Portfolio.......61 New Cardiac Monitoring Products from Philips.......61 Siemens Launches Image-Arena.......61 Siemens Announces New Procam-Calculator Combined with CT Examination.......611 Siemens Medical Solutions Launches Axiom Artis dTA.......62 GE Healthcare Unveils Vivid i.......621 GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System.......63 GE Healthcare Debuts New Imaging System.......63 New Discovery PET/CT Systems from GE Healthcare.......63 SonoSite Presents SonoCalc IMT Software.......631 Dade Behring Introduces High Sensitivity Troponin I Assay.......64 Biosite Unveils New Diagnostic Test.......64 MDS Diagnostic Services Unveils New Test to Prevent Heart Disease.......641 diaDexus Develops PLAC Test.......65 Siemens Introduces New Nuclear Cardiology Imaging System.......65 Roche Diagnostics Receives U.S. Clearance and European CE Mark.......651 Camtronics Unveils Cardiovascular Screening Software.......66 Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test.......661 10. RECENT INDUSTRY ACTIVITY.......679 Inverness Changes Name to Alere.......67 Miraculins Acquires PreMD抯 PREVU(i) Skin Cholesterol Test Assets.......67 Kardia Health Systems Partners with TomTec Imaging Systems.......67 TriLink and Biofortuna Ink Licensing Agreement.......671 Corgenix Enters into a Strategic Alliance with ELITech.......68 VaxGen to Merge with diaDexus.......68 St. Jude Medical to Take Over LightLab Imaging.......681 GE Healthcare and CardioDx Enter into Strategic Alliance.......69 bioMerieux and Knome Ink Strategic Partnership Agreement.......69 Merge Healthcare Acquires AMICAS.......691 Diamedix and Nova Ink Distribution Agreement.......70 Inverness Acquires Standard Diagnostics.......70 Quidel Acquires Diagnostic Hybrids.......70 bioM閞ieux Acquires Meikang Biotech.......701 Aurora Health Care Partners with Celera.......71 Mediscience Technology Corporation Acquires SensiVida Medical Systems.......71 Volcano Acquires Axsun Technologies.......71 Thermo Fisher Takes Over B.R.A.H.M.S........711 SonoSite Acquires CardioDynamics International.......72 IntriCon Snaps Up Datrix.......72 ST. Jude Medical Receives US FDA and European Approval for EnSite Velocity?Cardiac Mapping System.......72 Roche Inks Agreement with Response Biomedical.......721 Dynatek Dalta Scientific Inks Agreement with State Food and Drug Administration.......73 Amic Inks Licensing Deal with Roche Diagnostics.......73 TRICARE Includes Atherotech抯 VAP?Test.......731 PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol Test.......74 Amic Gains License for Roche抯 Cardiac Marker.......74 diaDexus and Fisher HealthCare Sign Agreement.......741 Inverness Inks Distribution Agreement with PrognostiX.......75 GE Healthcare Enters into Collaboration with Boston Scientific.......75 St. Jude Medical Acquires EP MedSystems.......751 11. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER.......7616 Inverness Takes Over Biosite.......76 Siemens Medical Acquires Dade Behring.......76 Inverness Medical Innovations Acquires Cholestech.......761 Acrongenomics, Pearson and Molecular Enter into Joint Venture.......77 Cholestech Teams Up with Onsite Health Diagnostics.......77 Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests........771 Transgenomic and Fiuotecnica Renew Collaboration Agreement.......78 Alteon and BioRap Technologies Enter into an Agreement.......78 IM Medical Acquires New Technology for Detecting Cardiovascular Diseases.......78 Medtronic Establishes New Business Entity.......781 Siemens Medical Acquires Bayer Healthcare抯 Diagnostics Unit.......79 Inverness Medical Innovations Completes Acquisition of HemoSense.......79 Spacelabs Acquires Ferraris?Cardiac Unit.......791 Global Immune Takes over Primedical International.......80 Siemens Acquires Diagnostics Products.......80 Cholestech and Life Line Enter into Collaboration.......80 LipoScience Signs an Agreement with ARUP.......80 Philips Acquires Witt Biomedical.......801 CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray.......81 Biosense Enters into Strategic Partnership with Siemens Medical Solutions.......81 Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica.......81 Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF.......811 Nanogen Acquires Spectral抯 Cardiac Test Division.......82 Varian Enters into Alliance with LipoScience to Jointly Develop NMR System.......82 Cardiac Services Professionals Establish eCardio Diagnostics.......821 Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin T.......83 Biomerieux gains Nonexclusive License for NT-proBNP.......83 Philips and PMI Ink an Agreement for Outpatient Facility.......83 LipoScience Enters into an Agreement with LabCorp.......83 Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test.......831 Abbott Receives 510(k) Clearance from FDA for Myoglobin Test.......84 FDA Clears Additional Claim for Biosite抯 Triage (R) BNP Test.......84 Biosite Inks an Agreement with University of Mainz.......84 Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay.......84 Nanogen Acquires SYN昘 Pharma.......841 GE Takes Over Amersham Plc.......85 St. Jude Medical Acquires Irvine Biomedical and Epicor.......85 SonoSite Snaps Up SonoMetric.......85 CardioDynamics Acquires Vermed.......85 Philips and EP MedSystems Announce an Alliance Involving Electrophysiology Solutions.......85 Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of Medicine.......851 Response Biomedical Collaborates with Shionogi.......86 Terumo Signs Agreement with Spencer Technologies.......86 Spectral Diagnostics Announces Agreement with NGC Medical.......86 Philips Signs Agreement with Fletcher Allen Health Care.......86 Spectral Diagnostics Enters into an Agreement with Cardinal Health.......86 Siemens Signs Agreement with MediGuide.......861 Biosite Enters into Agreement with DMI BioSciences.......87 Cambridge Heart Enters into Agreement with Del Mar Reynolds.......87 Cholestech Enters into an Agreement with Itamar Medical.......87 Siemens Enters into a Contract with HiPGraphics.......871 Abbott Announces US Clearance for Axis-Shield抯 BNP Test for Use on AxSYM.......88 Cholestech Announces FDA 510(k) Approval for hs-CRP Test.......88 Dade Behring Bags FDA Clearance NT-proBNP Test.......88 Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay.......88 EP-4 Computerized Cardiac Stimulator Bags FDA Approval.......88 Biosite Adds two new offices.......881 Bayer Diagnostics Enhances BNP Assay Offering Globally.......89 EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe.......89 Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact.......891 EPIX and Schering AG Extends Collaboration Agreement.......90 Siemens Ultrasound and TomTec Imaging Systems Announces Agreement.......90 FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular Devices.......90 Beckman Coulter Enters into Agreement with Biosite.......901 Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker.......91 Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop CardioGen-82?......91 New Lab Test from diaDexus Receives FDA Clearance.......91 Hypertension Diagnostics Receives SDA Approval in China.......911 12. FOCUS ON SELECT GLOBAL PLAYERS.......9210 AccuTech, LLC (USA).......92 Abbott Diagnostics (USA).......92 Alere Inc. (USA).......922 Biosite, Inc. (USA).......94 Ani Biotech Oy (Finland).......94 Axis-Shield PoC (UK).......941 Beckman Coulter, Inc. (USA).......95 biom閞ieux (France).......95 Cambridge Heart, Inc. (USA).......951 Cholestech Corp. (USA).......96 GE HealthCare (UK).......961 Home Access Health Corporation (USA).......97 LifeSign LLC (USA).......97 Liposcience, Inc. (USA).......971 Nanosphere, Inc. (USA).......98 Ortho-Clinical Diagnostics, Inc. (USA).......98 Philips Healthcare (USA).......981 Polymer Technology Systems, Inc. (USA).......99 Response Biomedical Corp. (Canada).......991 Roche Diagnostics (Switzerland).......100 Siemens Healthcare Diagnostics, Inc. (USA).......1001 St. Jude Medical, Inc. (USA).......101 EP MedSystems (USA).......1011 13. GLOBAL MARKET PERSPECTIVE.......102 Table 11: World Recent Past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1021 Table 12: World Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East, and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1031 Table 13: World 11-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1041 Table 14: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1051 Table 15: World Historic Review for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1061 Table 16: World 11-Year Perspective for Cardiovascular In Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1071 Table 17: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1081 Table 18: World Historic Review for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1091 Table 19: World 11-Year Perspective for Cardiovascular In Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1101 14. THE UNITED STATES.......11112 A. Market Analysis.......111 Trends and Issues.......111 Innovations Drive the Usage of Cardiovascular Monitoring Systems.......111 Cholesterol POCT Market: An Overview.......1111 Table 20: US Cholesterol Point-of-Care Testing (2009): Market Shares of Leading Players by Value Sales for Inverness Medical, Polymer Technology Systems, and Roche Diagnostics (includes corresponding Graph/Chart).......112 Increasing Cardiovascular Ailments Drive Sales of Home Test Devices.......112 CHF Biomarkers to Spearhead the US market.......1121 Table 21: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).......113 Table 22: US CHF (Congestive Heart Failure) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).......113 Cardiovascular Disease Prevalence in the US.......1131 Key Statistics on Cardiovascular Diseases.......114 Mortality Statistics.......1141 Table 23: Prevalence of Cardiovascular Disease in the US (2004): A Historic Review (includes corresponding Graph/Chart).......115
Table 25: Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex (2004): A Historic Review (includes corresponding Graph/Chart).......116 Table 26: A Factoid of CHD and MI (In Million) in the US (2003): A Historic Review.......116 Startling facts related to Stroke in US.......1161 Table 27: A Factoid of Stroke (In Million) in the US (2003): A Historic Review.......117 Incidence of Coronary Heart Disease.......117 AHA Statistics for Coronary Heart Disease.......1171 Mortality rates of CHD.......118 Table 28: Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex (2004) (includes corresponding Graph/Chart).......1181 Table 29: Prevalence of CHD by Age and Sex (2004) (In % population) (includes corresponding Graph/Chart).......119 Arrhythmias.......119 CAD Diagnostics.......1191 PVD Diagnostics.......120 Medicare Reimbursement Set for CPT Code 83704.......120 Competitive Glance.......120 Point-of-Care (POC) Diagnostics Market in the US.......1201 Table 30: Leading Players in the US POC Cardiac Market (2004) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart).......121 B. Market Analytics.......121 Table 31: US Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1211 Table 32: US Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......122 Table 33: US 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 & 2015.......1221 15. CANADA.......1232 A. Market Analysis.......123 Cardiovascular Disease Facts.......123 B. Market Analytics.......123 Table 34: Canadian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1231 Table 35: Canadian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......124
16. JAPAN.......1252 Market Analysis.......125 Table 37: Japanese Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1251 Table 38: Japanese Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......126
17. EUROPE.......1277 A. Market Analysis.......127 In Vivo Diagnostics ?Major Segment in CVD Diagnostics Market.......127 Germany - The Largest European Market.......127 Cardiovascular Disease ?Mortality Statistics.......1271 Table 40: Leading Cause of Death Among Men in Europe (2007): Percentage Breakdown for Cardiovascular Diseases, Poisoning and Injuries, Respiratory Disease, Cancer, and Others (includes corresponding Graph/Chart).......128
Cardiovascular Disease ?Risk Factor Profile.......1281 The Cardiovascular Disease Cost Burden.......129 B. Market Analytics.......129 Table 42: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1291 Table 43: European Historic Review for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1301 Table 44: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1311 Table 45: European Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......1321 Table 46: European 11-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).......133
17a. FRANCE.......1342 Market Analysis.......134 Table 48: French Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1341 Table 49: French Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......135
17b. GERMANY.......1362 Market Analysis.......136 Table 51: German Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1361 Table 52: German Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......137
17c. ITALY.......1382 Market Analysis.......138 Table 54: Italian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1381 Table 55: Italian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......139
17d. THE UNITED KINGDOM.......1403 A. Market Analysis.......140 UK Cardiovascular Diseases Fact Sheet.......1401 B. Market Analytics.......141 Table 57: UK Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1411 Table 58: UK Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......142
17e. SPAIN.......1432 Market Analysis.......143 Table 60: Spanish Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1431 Table 61: Spanish Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......144
17f. RUSSIA.......1453 A. Market Analysis.......145 Major Players.......1451 B. Market Analytics.......146 Table 63: Russian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1461 Table 64: Russian Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......147
17g. REST OF EUROPE.......1482 Market Analysis.......148 Table 66: Rest of Europe Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1481 Table 67: Rest of Europe Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......149
18. ASIA PACIFIC.......1505 A. Market Analysis.......150 Cardiovascular Market in Asia-Pacific.......150 China.......150 Healthcare Expenditure to Grow Considerably by 2015.......1501 In vitro Diagnostics Market Poised for Strong Growth.......151 Domestic Manufacturers Pose a Threat for Overseas IVD Manufacturers.......151 Leading Players.......151 Cardiovascular Disease Patients Overview.......1511 Treatment Providers and Hospitals Overview.......152 Hospitals.......152 Table 69: Cardiovascular Special Treatment Hospitals in China: 1991-2011(In numbers) (includes corresponding Graph/Chart).......152 Chinese Cardiovascular Disease Treatment as a Part of Overall Health Care Industry.......1521 Table 70: Cardiovascular Disease Treatment in China: 1991-2006 (includes corresponding Graph/Chart).......153 B. Market Analytics.......153 Table 71: Asia-Pacific Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1531 Table 72: Asia-Pacific Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......154
19. THE MIDDLE EAST.......1552 Market Analysis.......155 Table 74: The Middle East Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).......1551 Table 75: The Middle East Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......156
20. LATIN AMERICA.......1573 A. Market Analysis.......157 Brazil: A Growing Market for IVD.......157 Table 77: Brazilian IVD Market by Segment (2009): Percentage Share Breakdown for Immunoassay, Hormone, Microbiology, Biochemistry, Hematology, Molecular Diagnostics, Cardiac markers, Hemostasis, and Cytology (includes corresponding Graph/Chart).......1571 B. Market Analytics.......158 Table 78: Latin American Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1581 Table 79: Latin American Historic Review for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).......159 Table 80: Latin American 11-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2010 & 2015.......1591 COMPETITION305 Total Companies Profiled: 71 (including Divisions/Subsidiaries - 82)
The United States 57 Canada 3Japan 4Europe 15 France 1 Germany 1 The United Kingdom 5 Italy 3 Rest of Europe 5Asia-Pacific (Excluding Japan) 1Middle-East 2 
Click here to request a full table of contents and more details on this project. 窗体底端 |
